Novo Nordisk A/S (Novo Nordisk A/S) Research & Development : $4,698 Mil (TTM As of Dec. 2023)

View and export this data going back to 1981. Start your Free Trial

What is Novo Nordisk A/S Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Novo Nordisk A/S's Research & Development for the three months ended in Dec. 2023 was $1,530 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 was $4,698 Mil.

Novo Nordisk A/S Research & Development Historical Data

The historical data trend for Novo Nordisk A/S's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk A/S Research & Development Chart

Novo Nordisk A/S Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Research & Development

Get a 7-Day Free Trial

2,115.16

2,528.37

2,700.50

3,424.08

4,746.74

Novo Nordisk A/S Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Research & Development	Get a 7-Day Free Trial															1,151.23	967.75	1,037.12	1,163.19	1,530.40

Novo Nordisk A/S Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $4,698 Mil.

Novo Nordisk A/S (NYSE:NVO) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Novo Nordisk A/S Research & Development Related Terms

Thank you for viewing the detailed overview of Novo Nordisk A/S's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Novo Nordisk A/S (Novo Nordisk A/S) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novo Nordisk A/S (NYSE:NVO) » Definitions » Research & Development

Comparable Companies

Traded in Other Exchanges

NONOF:USA NOVOB:Mexico NVO:Mexico NOVOBc:UK 0QIU:UK NOVO B:Denmark NOV:Germany NOV:Germany NOVA:Germany NOV:Germany NOV:Germany NOVA:Germany N1VO34:Brazil NNO2:Austria

Address

Novo Alle 1, Bagsvaerd, DNK, DK-2880

Website

https://www.novonordisk.com

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.